Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Retatrutide is administered as a once-weekly subcutaneous injection, consistent with the dosing schedule used by other incretin-based therapies
Phase 2 and interim phase 3 clinical trial data demonstrate robust effectiveness of GLP-1 RAs in achieving MASH resolution, with semaglutide showing additional promise for fibrosis improvement in the ongoing ESSENCE trial
95% CI, 1.26-1.56), but shorter duration (=26 weeks) of treatment was not (RR 0.79)
Neutralizes free radicals and prevents cellular oxidative damage
adults now takes a GLP-1, but that average hides a sharp pattern by age
US$ 21.70
US$ 24.47
US$ 25.40
US$ 22.83
